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Abstract
Background: Therapeutic drug monitoring of immunosuppressive drugs in organ-transplanted patients is crucial to
prevent intoxication or transplant rejection due to inadequate dosage. The commonly used immunoassays have
been gradually undergoing replacement by mass spectrometry, since this physical method offers both a higher
sensitivity and specificity. However, a switch should be carefully considered because it is a challenging procedure
and needs to be thoroughly validated.
From an economic perspective it is reasonable to include mycophenolic acid into the assay, because this saves the
necessity for an additional measurement. However, to date very few validation protocols for the measurement of
immunosuppressants, including mycophenolic acid, are available. In order to adequately compensate for matrix
effects, the use of stable isotope labeled internal standards is advisable. Here, the authors describe a single method
suitable for the quantification of cyclosporine A, tacrolimus, sirolimus, everolimus and mycophenolic acid, based on
deuterated internal standards.
Methods: Plasma proteins were precipitated with zinc-sulfate, followed by an online solid phase extraction in the
flow-through direction. Chromatographic separation was performed by a c18-phenyl-hexyl column. For subsequent
mass spectrometric analysis stable-isotope-labeled internal standards were used. Results were available after 3.5
minutes.
Results: Low quantification limits (accuracy: 104 - 118%) and linearity resulted in 2 -1250 ng/ml for cyclosporine A;
0.5 - 42.2 ng/ml for tacrolimus; 0.6 - 49.2 ng/ml for sirolimus; 0.5 - 40.8 ng/ml for everolimus and 0.01 - 7.5 μg/ml
for mycophenolic acid. Intra-assay precision revealed a coefficient of variation (CV) of 0.9 - 14.7%, with an accuracy
of 89 - 138%. The CV of inter-assay precision was 2.5 - 12.5%, with an accuracy of 90 - 113%. Recovery ranged from
76.6 to 84%. Matrix effects were well compensated by deuterated internal standards.
Conclusions: The authors present a fast, economical and robust method for routine therapeutic drug monitoring
comprising five immunosuppressants including mycophenolic acid.
Background
Therapeutic drug monitoring (TDM) of immunosup-
pressive drugs in organ-transplanted patients is vitally
important to prevent intoxication or rejection due to
incorrect dosage. New therapeutic regimens combine
immunosuppressants with different intracellular targets
to lower blood concentrations and prevent undesired
side effects [1-3]. This practice requires a precise and
accurate analytical method, especially for the lower
ranges of concentrations. With regards to sensitivity
immunoassays often fail to meet clinical needs, due to
their restricted detection limits. Moreover, they are vul-
nerable to cross-reactions against pharmacologically
inactive metabolites, resulting in limited specificity and
possibly false results [4].
In order to minimize imprecision at low drug concen-
trations, elaborate sample preparation is required to
separate the molecules of interest from the patient’s
blood matrix molecules [5]. Any remaining matrix can
adversely affect the efficiency of ionization and lead to
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erroneous results. Thus, matrix effects need to be identi-
fied and compensated by internal standards (IS). Since
stable isotope labeled, structurally analogous isoforms
are the most appropriate controls for matrix compensa-
tion [6,7], deuterated equivalents are about to replace
the common IS ascomycin, cyclosporine D (CSD) [8-10]
and carboxy butoxy ether of mycophenolic acid
(MPAC).
Cyclosporine A (CSA), tacrolimus (TAC), everolimus
(EVE) and sirolimus (SIR) are measured in whole blood,
whereas mycophenolic acid (MPA) is determined in
plasma [11,12]. Several methods have been reported to
measure these drugs using different techniques for sam-
ple preparation and high pressure liquid chromato-
graphic (HPLC) schedules [8,13-15]. However, these
applications lack either appropriate IS or MPA to com-
plete the analytical spectrum. Moreover, the separation
of the main MPA metabolite mycophenolic acid glucur-
onide (MPAG) is essential for mass spectrometric analy-
sis because MPAG can undergo in-source fragmentation
to MPA via loss of the glucuronic acid moiety [11],
which in the case of coelution is determined as MPA.
Generally, sample preparation consists of precipitation
with a mixture of zinc-sulfate, organic solvent (metha-
nol, acetonitrile or acetone) and IS, usually CSD, asco-
mycin and MPAC. The method proposed by Koster et
al. for example precipitates proteins using zn-sulfate
only for CSA and TAC, but not for SIR and EVE [16].
This approach has the disadvantage of requiring sepa-
rate runs to get all of the analytes quantified.
Adding water before precipitation prevents sample
clotting and improves extraction efficiency [17]. How-
ever, due to higher dilution this procedure needs a
highly sensitive mass spectrometer.
One step that most sample preparation protocols
described in the literature have in common is that after
precipitation debris and contaminants must be removed,
before the extracts undergo testing.
This necessitates two-dimensional chromatography
with a 6 or 10 port switching valve. First, the sample is
injected into the extraction column with aqueous
extraction buffer containing a low concentration of
organic solvent, after which it is then flushed at high
flow rates (up to 5 ml/min). After valve switching, the
organic buffer usually is run in back-flush mode to elute
the analytes to the analytical column.
Another frequently used method is solid phase extrac-
tion in offline mode, which resembles the online proce-
dure. The main difference is the desiccation of the
eluted analytes under an airstream, followed by reconsti-
tution in analytical buffer, before the sample can be
injected into the HPLC-device.
This paper presents the complete validation of a single
LC-MS/MS method for five immunosuppressants,
including MPA, based on protocols described by Annes-
ley et al. [17] and Seger et al. [15]. CYA, TAC, SIR and
EVE were analyzed simultaneously in a single analytical
run, whereas MPA was analyzed separately due to its
preparation from plasma. To our knowledge this is the
first application using corresponding deuterated IS
(CSA-d4, TAC-13C-d2, EVE-d4, SIR-13C-d3, and MPA-
d4) for each immunosuppressant and identical HPLC
running conditions for all analytes. The use of an online
solid-phase extraction in straight flush mode makes this
application suitable for the determination of MPA as
well.
Methods
The protocol described in this paper follows internation-
ally accepted guidelines (NCCLS, FDA) for the valida-
tion of in-house methods [18,19].
Patient material was used in anonymous form in con-
sent with the ethics committee of the University Medi-
cal Faculty, Freiburg. According to the guidelines of
ICMJE and WHO a study registration was not required.
Reagents and materials
Immunosuppressants CSA, TAC, SIR and MPA, as well
as water, methanol, acetic acid and ammonium acetate
in LC-MS quality were purchased from Sigma-Aldrich
(Munich, Germany). EVE was kindly provided by Novar-
tis (Basel, Switzerland). MPAC was a kind gift of Roche
Palo Alto, California. Zinc sulfate heptahydrate was sup-
plied by Merck (Darmstadt, Germany).
Deuterated standards CSA-d4, TAC-
13C-d2, EVE-d4
and MPA-d3 were obtained from Toronto Research
Chemicals (Ontario, Canada) and SIR-13C-d3 from Alsa-
chim (France). For calibration and quality control the
6Plus1 multilevel calibration kit and 4-level whole-blood
controls of Chromsystems (Munich, Germany) were
used. Calibrator and controls for MPA were provided by
Recipe (Munich, Germany).
Sample preparation
The concentrations of IS were adjusted to the area
under the curve (AUC) of calibrator 2 (MPA: control 2)
and were 50 μg/ml for CSA-d4, 0.8 μg/ml for TAC-
13C-
d2, 0.8 μg/ml for SIR-
13C-d3, 0.25 μg/ml for EVE-d4 and
6 μg/ml for MPA-d3.
The working solution was prepared fresh daily and
consisted of 30 ml methanol, 15 ml zinc sulfate solution
(0.1 M) and 100 μl IS-Mix - sufficient for the treatment
of 120 samples.
Samples were prepared according to the protocol
described by Annesley et al. [17] and Seger et al. [15]
with modifications as follows: 50 μl EDTA whole blood
were taken for each sample to determine CSA, TAC,
SIR and EVE, but 50 μl EDTA plasma was used to
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analyze MPA. In the instances of patients treated with a
combination therapy including MPA, an aliquot of the
EDTA sample was taken for plasma extraction just
before the preparation of whole blood for CYA, TAC,
SIR or EVE analysis. The latter were analyzed simulta-
neously in a single analytical run. Therefore, the plasma
and whole blood preparations had to be injected sepa-
rately. However, apart from different starting material,
all preparation steps and analytical conditions were
identical.
Samples, controls and calibrators were first mixed on
a roller, hemolysed by adding 125 μl of water, thor-
oughly vortexed and then incubated for two minutes at
room temperature (RT). The next step was an ultrasonic
bath for 20 sec (omitted in the case of MPA). Initially,
time dependent progression of hemolysis was confirmed
by microscopy: immediately after the addition of water;
then after 2 minutes of incubation with water and finally
after 2 minutes incubation with water plus 20 sec of
ultrasonic treatment. After the addition of 375 μl work-
ing solution samples were vortexed, kept for 10 minutes
at RT and centrifuged at 15000 g (10 min). The super-
natants were subsequently transferred to autosampler
vials. The described procedure corresponds to a final
dilution of 1:11 (v/v). To clarify whether matrix effects
can be affected by a different dilution ratio, dilutions of
1:3 and 1:21 were carried out in parallel.
Liquid chromatography
For chromatographic separation, a Shimadzu Promi-
nence HPLC system equipped with three isocratic
pumps was used. The injection volume was 2 μl for
MPA and 20 μl for the remaining immunosuppressive
drugs. For online purification a solid phase extraction
column (SPE) Poros R1/20, 2.1 mmD × 30 mm, 20 μm
(Applied Biosystems, Darmstadt, Germany) was chosen.
A phenyl-hexyl reversed phase C18 column Zorbax
Eclipse XDB (Agilent, Waghäusel, Germany) 3.0 × 75
mm, 3.5 μm at 60°C was used as the analytical column.
Column switching was controlled by a multi-channel
valve (Valco 10 port 2 position valve) according to the
pattern shown in Figure 1.
After injection, the SPE column was loaded for one
minute with aqueous eluent (90:10 v/v, water/methanol
containing 10 mM ammonium acetate and 0.1% acetic
acid) at a flow rate of 5.0 ml/min. After valve switching
organic molecules were eluted to the analytical column
with methanolic buffer (97:3 v/v, methanol/water, 10
mM ammonium acetate and 0.1% acetic acid) at a flow
rate of 0.9 ml/min. During that time both columns were
connected in series, so that the flow direction corre-
sponded to the loading direction. After switching the
valve to the starting position, the Poros column was
rinsed with pure methanol at 1 ml/min, to remove any
remaining organic molecules and prevent carry-over
contamination.
A 40 sec conditioning phase of the SPE column with
aqueous buffer at a flow rate of 5 ml/min completed the
run to a total analysis time of 3.5 min.
Mass spectrometry
Mass spectrometric analysis was run on an API 4000
(AB Sciex, Darmstadt, Germany) equipped with an elec-
trospray ionization interface (ESI). Analyte-specific vol-
tage settings and ion-source adjustment were set
manually, the former after automatic optimization. Gas
settings in ml/min were: Collision gas: 7, curtain gas: 20,
ion source gas 1: 50, ion source gas 2: 75, ion spray vol-
tage: 5500 V, and temperature: 400°C. Ammonium
adducts of each analyte were detected in positive ion
mode by multiple-reaction-monitoring. Mass transitions
can be found in Table 1. There is no qualifier for
MPAG since this metabolite was not quantified but only
monitored.
Validation methods
In order to determine the limit of quantification (LOQ)
blank calibrator was spiked with low calibrator to obtain
Figure 1 Column Switching. Pos A: Conditioning of the analytical column and loading of SPE column with aqueous buffer containing 10%
methanol. Pos B: Elution from the analytical column (97% methanolic solvent) and rinsing step of precolumn with pure methanol.
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the desired concentration. All calibrators and controls
were reconstituted according to the manufacturer’s
instructions, aliquoted and then frozen at -20°C. The
LOQ was defined as the lowest measurable concentra-
tion which could be determined with a CV below 10%.
For this, drug free blood was spiked with calibrator 1
(lowest concentration) to a concentration of 2 ng/ml for
CSA, 0.5 ng/ml for TAC, 0.65 ng/ml for SIR and 0.55
ng/ml for EVE. The final concentrations varied due to a
calibrator-saving common preparation step.
For MPA, plasma calibrator was prepared with drug-
free plasma to a final concentration of 0.01 μg/ml. Ali-
quots of all three stock solutions were frozen.
Samples for the detection of linearity were prepared in
drug-free blood pooled with calibrator 6 (highest con-
centration) at three different ratios (1:2, 1:4 and 4:1), to
obtain a graph consisting of five data points. Native cali-
brator level 6 and blank blood served as starting points.
In the case of MPA, drug-free plasma was spiked with
mycophenolate to a concentration of 7.5 μg/ml and pre-
pared in the same way. Final concentrations were as fol-
lows: CSA (blank; 224; 448; 672 and 896 ng/ml); TAC
(blank; 10.6; 21.1; 31.7 and 42.2 ng/ml); SIR (blank; 12.3;
24.6; 36.9 and 49.2 ng/ml); EVE (blank; 10.2; 20.4; 30.6
and 40.8 ng/ml); MPA (blank; 1.88; 3.75; 5.63 and 7.50
μg/ml).
All specimens were aliquoted and stored at -20°C. To
match the higher C2-values (blood concentration two
hours after application), CSA dilutions were carried out
with spiked whole blood up to 2000 ng/ml, because the
highest calibrator level reaches just 896 ng/ml.
Precision tests were performed with drug-free whole
blood samples from patients attending different clinical
departments (internal medicine, surgery and gynecol-
ogy). Enrichment with methanolic stock solutions of
each drug yielded three ascending concentrations (low-
est concentration = LOQ concentration). Due to the
large volume required (3 ml for each drug and concen-
tration add up to approx. 50 ml in total), the assays
were not performed with certified controls. Further-
more, the use of the patient material came closest to the
clinical environment. After gentle mixing for four hours
on a roller mixer, samples were aliquoted and stored at
-20°C until use.
For the intra-assay precision test, each concentration
was extracted five times and measured in series.
The same specimens were used to detect the inter-
assay precision on twenty continuous days (measured
once), according to a new daily calibration.
To detect interference due to coeluted matrix consti-
tuents, the postcolumn infusion method as published by
Taylor and Vogeser was implemented [7,20]. For this
purpose methanolic solutions containing the immuno-
suppressants (500 ng/ml) were infused, while injecting
analyte-free extracts of whole blood samples. Methanolic
drug dilution was supplied at a constant flow rate of 10
μl/min to the HPLC flow of 0.9 ml/min with a T-piece
directly before the ESI source, resulting in a further
dilution of 1:90. After injecting drug-free blood matrix
or methanol, total ion count (TIC) of the particular
drug was monitored during the entire analytical cycle.
Process efficiency and recovery were tested by means
of addition at pre- and post-extraction steps. For each
analyte before sample preparation, drug free blood was
spiked with three concentrations of methanolic stock
solutions (CSA: 10, 100, 500 ng/ml, TAC, SIR, EVE: 2,






Cyclosporine A-d4 1224.0 1206.9 Cyclosporine A 1219.9 1203.0
Tacrolimus13C-d2 824.6 771.6 Tacrolimus 821.5 768.4
Sirolimus-13C-d3 935.6 864.6 Sirolimus 931.6 864.7
Everolimus-d4 979.6 912.6 Everolimus 975.6 908.5
Mycophenolic acid-d3 341.2 210.1 Mycophenolic acid 338.2 207.1
Mycophenolic acid glucuronide 513.6 207.2






Cyclosporine A-d4 1224.0 1188.8 Cyclosporine A 1219.9 1185.0
Tacrolimus13C-d2 824.6 789.4 Tacrolimus 821.5 786.5
Sirolimus-13C-d3 935.6 882.4 Sirolimus 931.6 882.4
Everolimus-d4 979.6 930.5 Everolimus 975.6 926.6
Mycophenolic acid-d3 341.2 306.3 Mycophenolic acid 338.2 210.1
Carboxy butoxy ether of mycophenolic acid 438.2 195.0
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5, 10 ng/ml, and MPA: 0.5, 1, 5 μg/ml). The results were
related to extracts that were enriched with correspond-
ing methanolic stock solutions.
The stability of the extracted samples was checked by
repeated determination after five hours (four patient
samples were used for each analyte). The samples were
kept cool throughout this time period in the
autosampler.
An integral element of further quality assurance was
the continuous participation in the international profi-
ciency-testing scheme (Prof. Holt, London). For CSA,
TAC and SIR three samples were supplied each month,
for EVE three samples six times per year and for MPA
two samples four times per year. Each scheme included
samples which were either spiked to a known concen-
tration or were pooled from patients receiving the target
drug. Aliquots of these samples were extracted and mea-
sured on a daily basis for five consecutive days.
Results
At the beginning of this validation, erythrocyte lysis was
confirmed microscopically. In later tests it was checked
only on a random basis. Ultrasonic treatment was intro-
duced as a result of an inacceptable CV (> 15%) for
inter-assay precision at the beginning of the validation
process. Without ultrasonic treatment lysis was incom-
plete, so that numerous red blood cells remained unda-
maged. However, the ultrasound treated samples were
lysed completely (Figure 2).
The advantage of stable-isotope-labeled isoforms for
use as IS was shown by the variant ionization behavior
of analytes and the corresponding deuterated standards
compared to CSD and ascomycin in two different lots of
certified control materials. In this case the signal for
CSA and CSA-d4 increased to a similar extent (by
100%) compared to the previous lot, resulting in a cor-
rect calculation of the target value. In contrast, the sig-
nal for CSD rose only by half, leading to a false ratio
and overestimation of the CSA target value.
The patients’ samples were also measured in parallel
using CSD and CSA-d4 as IS. In some cases the values
calculated with CSD differed by 60% - 150% from the
results obtained with CSA-d4. Comparable results could
be obtained for ascomycin and TAC-13C-d2, EVE-d4 and
SIR-13C-d3 respectively. Due to the experience with the
certified control material and its known target values,
further use of CSD and ascomycin was stopped.
A summary of validation results is depicted in Table 2.
All drugs revealed linear behavior up to the highest con-
centration of calibrator. Assay ranges were 2 - 1250 ng/
ml for CSA; 0.5 - 42.2 ng/ml for TAC; 0.6 - 49.2 ng/ml
for SIR; 0.5 - 40.8 ng/ml for EVE and 0.01 - 7.5 μg/ml
for MPA. The coefficient of determination (r2) was at a
minimum of 0.997. Assay sensitivity as well as data for
precision and accuracy exceeded clinical requirements,
as defined as a minimum sensitivity of at least 1 ng/ml
for TAC, SIR and EVE, 10 ng/ml for CSA and 0.02 μg/
ml for MPA, and a CV for precision and accuracy below
20%. Surprisingly, the CV for LOQ concentrations was
lower than for intra-assay precision.
The calibration results are summarized in Table 3.
Recovery after sample preparation resulted in a pro-
cess efficiency of 84 ± 0.6% for TAC, 80.7 ± 1.4% for
EVE, 80.2 ± 1.3% for CSA, 77.1 ± 2.6% for SIR and 76.6
± 1.9% for MPA.
Figure 3 shows exemple chromatograms of patient
samples for each analyte and their corresponding IS.
Additionally, common IS are compared with deuterated
IS. All peaks exhibit a nearly symmetrical shape; reten-
tion of analytes and deuterated standards are concor-
dant in time, whereas the common standards show a
slight difference in retention time.
The additional rinsing of the SPE column with metha-
nol for one minute, during separation in the analytical
column, doubled the column lifetime to at least three
months or 4500 analyses. The analytical quality,
reflected by the shape of the peaks, remained stable
throughout this time.
Figure 4 depicts the monitoring of matrix effects by
means of post column infusion in conjunction with the
corresponding retention times. The graphical time
course of the total ion count is illustrated by the CSA
figure. After the valve switch to methanolic buffer (A),
the sample was flushed to the analytical column. Strong
Figure 2 Microscopic images of whole blood (50 μl) incubated with water (125 μl) for various times. A: immediately after adding water B:
2 min incubation with water C: 2 min incubation with water plus 20 sec of ultrasonic treatment.
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ion loss occurred during the following elution of aqu-
eous buffer from the SPE column to the analytical col-
umn (C). Reconditioning of the SPE column (B) started
at 1.9 min, when the valve switched back to position A.
A second signal loss appeared during the assumed elu-
tion of sample matrix (D).
Compared to methanol-based solutions, the three
tested dilutions of sample preparation exhibit distinct
matrix effects (Figure 4). As expected, these effects are
more pronounced at a lower sample dilution (1:3). Sur-
prisingly, the higher dilution of 1:21 resulted in stronger
matrix effects than the lower dilution of 1:11. Due to a
lack of significant reduction of matrix effects and
increased imprecision at higher dilutions, the 1:11 ratio
was chosen for further development of this application.
The time frame of ion suppression ranged from 2.15
to 2.5 min. With 2.21 min., the retention time of CSA
was within this time window, whereas TAC, SIR and
EVE were not affected (retention time: 2.10 min.). As
illustrated in terms of quality, CSA showed a high and
TAC a slight ion suppression, whereas SIR, EVE and in
MPA exhibited an ion enhancement. These effects were
offset by the deuterated internal standards.
Figure 5 depicts the distinct chromatographic separa-
tion of MPAG and MPA. The in-source fragmentation
of MPAG to MPA is shown by the signal of the m/z
338.1/207.1 trace within the MPAG peak. Concerning
MPA, comparative measurements of mass spectrometry
and immunoassay showed significantly different results
for samples with a high content of MPAG (data not
shown). This discrepancy of up to 50% reflects, among
other things, a high cross-reactivity of the antibody
against the glucuronide.
Sample stability, as confirmed by repeated measure-
ments of 15 extracted patient samples per analyte after
5 hours, resulted in a CV < 8%.
Participation in the international proficiency testing
scheme in 2010 (analytical services international ASI,
Prof. Holt, U.K) revealed a mean accuracy of 3.6% for
CSA, 10.2% for TAC, -3.5% for SIR, 2.1% for EVE and
-2.6% for MPA and confirmed the validity of the
method.
Discussion
When determining immunosuppressants in whole blood,
thorough sample preparation plays a crucial role. Com-
plete lysis of erythrocytes and protein precipitation are
mandatory for good reproducibility. We employed water
incubation in conjunction with ultrasound treatment to
ensure complete lysis, which was microscopically veri-
fied at the beginning of the validation process and
ensured high reproducibility of the measurements.
Water lysis alone left many erythrocytes undamaged and
compromised precision.
Second, internal standards play a key role in mass-
spectrometric analyses. The use of CSD, ascomycin and
MPAC as internal standards for the quantification of
immunosuppressants can cause measurement errors due
to an ionization process in the ESI source which devi-
ates from that of the analyte [6,7,20-22]. Initially, the
common standards were also used for this validation
protocol. However, especially for CSA, divergence of
Table 2 Validation results


















Cyclosporine A 2 - 1250 3.7 2 7.4 7.1 125/113
r2= 0.997 104 100 2.3 2.9 104/106
500 0.9 2.5 106/105
Tacrolimus 0.5 - 42.2 7.5 0.5 12.3 9.1 138/100
r2= 0.998 108 10 3.7 4.9 116/99
20 3.8 4.5 111/98
Sirolimus 0.62 - 49.2 4.6 1 12.0 11.5 125/107
r2= 0.999 106 10 5.1 5.0 100/102
20 5.0 4.9 108/102
Everolimus 0.53 - 40.8 6.4 1 14.7 12.5 89/90
r2= 0.999 118 10 2.9 6.9 97/96
20 5.1 5.7 102/97
MPA 0.01 - 7.5 7.0 0.02 11.0 9.8 97/102
r2= 0.999 105 0.2 1.3 3.2 97/97
5 1.6 3.0 102/99
(LOQ: low limit of quantification, CV: variation coefficient)
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ionization efficiency (analyte vs. IS) were so large that
the results were significantly distorted.
This effect became particularly evident in matrices of
two certified control materials. In this case, CSA was
subject to ion enhancement, resulting in 40% higher
values than the specified target. The use of deuterated
standards could compensate for these matrix effects and
resulted in correct recovery. One batch of calibrators
was also affected by this phenomenon. In routine clini-
cal measurements, matrix impacts based on (non-stan-
dardized) patient samples will always be a recurrent
problem, which could be overcome by the use of deuter-
ated standards.
Crucial for correct recovery is an IS which comes che-
mically as close as possible to the analyte. The close
chemical relationship leads to identical retention time,
so that IS and analyte are affected in the same way, and
matrix effects can be compensated for.
Ascomycin also exhibited an elution behavior depen-
dent on the sample matrix, making it liable to wide fluc-
tuations. By use of deuterated standards that eluted
concurrently with the analytes, we noted that measure-
ment errors, especially those caused by ion suppression
or enhancement, were nearly all compensated for.
In contrast to other laboratories, the working solution
for sample preparation was set up daily to avoid any
instability. Small sample batches contributed to a fast
processing time, which could be kept below one hour.
Repeated analyses of samples after five hours confirmed
the previous results and thus verified the stability of the
extracted samples.
The analysis time required for this method is 3.5 min-
utes. We are highly suspicious of attempts to shorten
analysis times to one minute [8], especially when dealing
with substances having a variety of metabolites like
CSA, as isobars may appear which interfere with the









Accuracy (%) Linear Regression
(1/x weighting)
Cyclosporine A 0 < 0 N/A y = 0.00419 × + 0.000559






Tacrolimus 0 < 0 N/A y = 0.145 × + 0.00678






Sirolimus 0 < 0 N/A y = 0.104 × + 0.0171






Everolimus 0 < 0 N/A y = 0.112 × + 9.76e-0.09






MPA 4.27 1-point calibration
linear through zero
y = 0.00494 x
r = 1.0
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analyte, skewing the results. The likelihood of such
interferences can be minimized by thorough HPLC
separation.
One issue in developing this application was the iden-
tification of the most appropriate sample dilution. The
initial dilution of 1:3 was raised to 1:21 so as to reduce
matrix effects and soiling of the equipment [17]. Later,
the dilution was reduced to 1:11 due to the observation
that higher dilutions failed in further reduction of
matrix effects and lead rather to greater imprecision, in
spite of the equipment’s sensitivity.
Precision was not only influenced by dilution but also
depended on the material used. Certified lyophilized
control material used for the determination of LOQ
revealed a lower CV than spiked patient’s blood for
intra- and inter-assay testing. This phenomenon may
possibly be explained by the different matrices.
Another factor of influence was the purity of the
reagents. Many annoying adducts became apparent in
water and methanol when using HPLC-grade reagents.
These adducts have considerably reduced the sensitivity.
As was noted by Annesley [23], we also observed sig-
nificant differences in signal strengths from the same
sample, even when using several LC/MS grades of
methanol from various companies.
Most laboratories employ an HPLC-UV method or
immunoassay to determine MPA. Our method herein
stands out not just because CSA, TAC, SIR and EVE
can all be measured in parallel, but because MPA can
also be quantified using the same application. How-
ever, due to the fact that no commercial calibrator is
available containing MPA, it is inevitable that a sepa-
rate calibration is necessary. The additional expendi-
ture is compensated by identical analytical conditions
and procedures for all analytes. In agreement with
results from other working groups, we failed to deter-
mine MPA in whole blood due to inadequate precision
and accuracy (personal communication). Currently
there is no explanation for this result. As a conse-
quence, sample preparation must be carried out with
plasma. However, additional UV-HPLC analysis for the
determination of MPA, as is customary in most labora-
tories, can be waived.
As mentioned above, the chromatographic separation
of MPAG and MPA is crucial due to in-source fragmen-
tation of MPAG to MPA, which is then added to the
intrinsic value of MPA in the case of coelution [11].
The extent to which this secession occurs is essentially
construct-dependent. Glucuronide splits off to such a
miniscule degree on our equipment that we could forgo
chromatographic separation, although for reasons of
safety, we do not. Different retention times for MPA
and MPAG could be realized by a flow-through proce-
dure on the online-SPE column.
Figure 3 Exemplary chromatograms of original routine patient samples containing 103 ng/ml CSA, 9.6 ng/ml TAC, 6.1 ng/ml SIR, 5.3
ng/ml EVE and 4.9 μg/ml MPA. Mass transitions are stated.
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Adequate separation of MPA from MPAG proved
impossible when we tried to shorten the analysis time to
2.5 minutes or using the back flush online SPE method.
We compared our method to LC-MS/MS methods
used by two university and commercial laboratories,
observing that our results differed strikingly from the
latter. This clearly illustrates that it is not just the
immunoassays which need to be standardized - the phy-
sical methods must be standardized as well in order to
guarantee comparability.
The wide divergence of LC-MS methods is reflected in
the international proficiency testing scheme’s evaluation
and is caused by differences in equipment, applications,
and sample preparation. Furthermore, this application is
regularly confirmed via national proficiency testing
(DGKL, Instand).
Surprisingly, the signal strengths of the analytes and
the IS differ significantly even when identically-con-
structed instruments from the same manufacturer are
used, because of the sources’ divergent ionization beha-
vior. By changing the heating units and probes we
observed an up to a ten-fold difference in signal strengths
when comparing three sources on two mass spectro-
meters. At this point, the manufacturer has a duty to
develop better standardization procedures in order to
improve quality control. Devices should not be tested
with a reference source, but with the supplied sources.
The prevalence of immunosuppressive combination
therapy allows dose reduction and minimizes undesir-
able side effects [2,24]. However, it makes greater
demands on the analysis systems used, especially con-
cerning precision and reproducibility [19]. This explains
why replacement of immunoassays by mass spectrome-
try is taking root - it offers significantly better sensitivity
and is highly specific for the drug’s parent compound,
without having cross reactivity to metabolites. In the
case of CSA, the average recovery of immunoassays is
up to 25% higher compared to mass spectrometry. This
difference is due to individually occurring metabolites
with unknown pharmacologic effects.
Figure 4 Monitoring ion suppression (post column infusion
method). The TIC of all immuno-suppressants when injected in
methanolic solution, 1:3, 1:11 and 1:21 diluted sample-matrix
respectively are shown. A: valve switch to methanolic buffer (97%
methanol). B: valve switch to aqueous buffer (10% methanol;
reconditioning of SPE column). C: strong loss of ions during straight
forward elution of aqueous buffer from SPE column. D: second loss
of signal during assumed elution of sample matrix (2.15 - 2.45 min).
Figure 5 Chromatographic separation of MPAG m/z 513.6/
207.2 (dotted line) and MPA m/z 338.2/207.1 (solid line). The
arrow indicates the in-source fragmentation of MPAG to MPA.
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In addition, economic considerations also favor the
mass-spectrometry based method. First, it is time saving
since a single analytical run is adequate for the determi-
nation of CSA, TAC, SIR and/or EVE in patients with
combination therapy. Although two analytical runs are
needed in the case of MPA co-administration, the saving
in time is still evident. Second, the authors were able to
reduce the reagent and consumable costs by more than
80% compared to the previously used immunoassays
(340,000 Euro/year for CSA, TAC and MPA vs. 50,000
Euro/year for all analytes).
Arguments against mass spectrometry are its high
acquisition costs, high skill level required of personnel,
and the complex validation process necessary, so that
academic expertise is indispensable. Moreover, in the
case of defects or maintenance, the laboratory may
require a back-up system.
But nevertheless, once the mass-spectrometric method
has been established, it is easy to use in daily routine.
Therefore, the authors recommend this method for
laboratories with high throughput such as university
hospitals with transplantation departments.
Conclusion
Before mass spectrometric applications can be employed
for routine clinical purposes or be considered to be a
gold standard, they must be subjected to a thorough
validation process. The use of deuterated internal stan-
dards is highly recommended since the commonly used
standards may cause analytical problems due to an ioni-
zation efficiency differing from that of the analyte.
Last but not least: without established standards the
findings from different laboratories cannot be reliably
compared.
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